These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36525494)

  • 1. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.
    Kaushik AK; Tarangelo A; Boroughs LK; Ragavan M; Zhang Y; Wu CY; Li X; Ahumada K; Chiang JC; Tcheuyap VT; Saatchi F; Do QN; Yong C; Rosales T; Stevens C; Rao AD; Faubert B; Pachnis P; Zacharias LG; Vu H; Cai F; Mathews TP; Genovese G; Slusher BS; Kapur P; Sun X; Merritt M; Brugarolas J; DeBerardinis RJ
    Sci Adv; 2022 Dec; 8(50):eabp8293. PubMed ID: 36525494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.
    Abu Aboud O; Habib SL; Trott J; Stewart B; Liang S; Chaudhari AJ; Sutcliffe J; Weiss RH
    Cancer Res; 2017 Dec; 77(23):6746-6758. PubMed ID: 29021138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
    Okazaki A; Gameiro PA; Christodoulou D; Laviollette L; Schneider M; Chaves F; Stemmer-Rachamimov A; Yazinski SA; Lee R; Stephanopoulos G; Zou L; Iliopoulos O
    J Clin Invest; 2017 May; 127(5):1631-1645. PubMed ID: 28346230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
    Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
    Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J
    Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[
    Pollard AC; Paolillo V; Radaram B; Qureshy S; Li L; Maity T; Wang L; Uddin MN; Wood CG; Karam JA; Pagel MD; Piwnica-Worms D; Millward SW; Fowlkes NW; Norton W; Engel BJ; Pisaneschi F; Zacharias NM
    Mol Imaging Biol; 2022 Dec; 24(6):959-972. PubMed ID: 35732988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.
    Shroff EH; Eberlin LS; Dang VM; Gouw AM; Gabay M; Adam SJ; Bellovin DI; Tran PT; Philbrick WM; Garcia-Ocana A; Casey SC; Li Y; Dang CV; Zare RN; Felsher DW
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6539-44. PubMed ID: 25964345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.
    Wolff NC; Pavía-Jiménez A; Tcheuyap VT; Alexander S; Vishwanath M; Christie A; Xie XJ; Williams NS; Kapur P; Posner B; McKay RM; Brugarolas J
    Oncotarget; 2015 Jul; 6(19):16951-62. PubMed ID: 26219258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reductive carboxylation supports growth in tumour cells with defective mitochondria.
    Mullen AR; Wheaton WW; Jin ES; Chen PH; Sullivan LB; Cheng T; Yang Y; Linehan WM; Chandel NS; DeBerardinis RJ
    Nature; 2011 Nov; 481(7381):385-8. PubMed ID: 22101431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.
    Courtney KD; Bezwada D; Mashimo T; Pichumani K; Vemireddy V; Funk AM; Wimberly J; McNeil SS; Kapur P; Lotan Y; Margulis V; Cadeddu JA; Pedrosa I; DeBerardinis RJ; Malloy CR; Bachoo RM; Maher EA
    Cell Metab; 2018 Nov; 28(5):793-800.e2. PubMed ID: 30146487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
    Metallo CM; Gameiro PA; Bell EL; Mattaini KR; Yang J; Hiller K; Jewell CM; Johnson ZR; Irvine DJ; Guarente L; Kelleher JK; Vander Heiden MG; Iliopoulos O; Stephanopoulos G
    Nature; 2011 Nov; 481(7381):380-4. PubMed ID: 22101433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
    Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
    Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy.
    Hoerner CR; Chen VJ; Fan AC
    Kidney Cancer; 2019 Feb; 3(1):15-29. PubMed ID: 30854496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
    Albiñana V; Recio-Poveda L; González-Peramato P; Martinez-Piñeiro L; Botella LM; Cuesta AM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.
    Gameiro PA; Yang J; Metelo AM; Pérez-Carro R; Baker R; Wang Z; Arreola A; Rathmell WK; Olumi A; López-Larrubia P; Stephanopoulos G; Iliopoulos O
    Cell Metab; 2013 Mar; 17(3):372-85. PubMed ID: 23473032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis.
    Ma Y; Qi Y; Wang L; Zheng Z; Zhang Y; Zheng J
    Free Radic Biol Med; 2019 Apr; 134():458-467. PubMed ID: 30703481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.